Richard Pzena
Pzena Investment Management
Richard Pzena Bristol-Myers Squibb Company stake
total: 576
Pzena Investment Management BMY trades
- Total transactions:
- 27
- New positions:
- 1
- Added:
- 14
- Reduced:
- 12
- Held since:
- 2019 Q3
- Held for:
- 27 quarters
- Latest activity:
- 2026 Q1
According to 2026 Q1 report, Richard Pzena holds 17,095,731 Bristol-Myers Squibb Company (BMY) shares with a market value of roughly $1.04B accounting for 3.37% of the overall portfolio. To date, the estimated cost basis is nearly $55.44 for "buy" trades and estimated average "sell" price is $59.54. Pzena Investment Management first purchased BMY in 2019 Q3, initially acquiring about 2.58M shares. Since the initial investment in Bristol-Myers Squibb Company (BMY), Pzena Investment Management has made 26 more transactions.
When did Richard Pzena buy Bristol-Myers Squibb Company (BMY)?
Richard Pzena first invested in Bristol-Myers Squibb Company (BMY) in 2019 Q3 at the reported quarter-end price of $50.71 per share.
What's the cost basis of Pzena Investment Management's BMY stake?
The estimated cost basis for Bristol-Myers Squibb Company (BMY) stake is around $55.44 per share. This represents their average reported price* across all buy transactions
Estimated cost basis*
- Weighted AVG buy price:
- $55.44
- Weighted AVG sell price:
- $59.54
Richard Pzena's historical trades in Bristol-Myers Squibb Company
27 results
| Period |
% of portfolio |
Shares held after* |
Reported price* |
Value* |
% (shares) of activity |
% change to portfolio |
|---|---|---|---|---|---|---|
|
2026 Q1
|
3.37%
|
17,095,731
|
$60.65
|
$1,036,856,085
|
-4.72% (-847,772)
|
-0.15%
|
|
2025 Q4
|
2.90%
|
17,943,503
|
$53.94
|
$967,872,552
|
+20.41% (+3,041,899)
|
+0.49%
|
|
2025 Q3
|
2.17%
|
14,901,604
|
$45.10
|
$672,062,341
|
+0.39% (+58,129)
|
+0.01%
|
|
2025 Q2
|
2.23%
|
14,843,475
|
$46.29
|
$687,104,458
|
+10.29% (+1,384,649)
|
+0.21%
|
|
2025 Q1
|
2.87%
|
13,458,826
|
$60.99
|
$820,853,797
|
+1.18% (+157,527)
|
+0.03%
|
|
2024 Q4
|
2.56%
|
13,301,299
|
$56.56
|
$752,321,471
|
-6.34% (-900,447)
|
-0.16%
|
|
2024 Q3
|
2.37%
|
14,201,746
|
$51.74
|
$734,798,338
|
+0.48% (+67,409)
|
+0.01%
|
|
2024 Q2
|
2.06%
|
14,134,337
|
$41.53
|
$586,999,016
|
+14.97% (+1,840,424)
|
+0.27%
|
|
2024 Q1
|
2.29%
|
12,293,913
|
$54.23
|
$666,698,902
|
+119.82% (+6,701,097)
|
+1.25%
|
|
2023 Q4
|
1.08%
|
5,592,816
|
$51.31
|
$286,967,389
|
+13.58% (+668,622)
|
+0.13%
|
|
2023 Q3
|
1.23%
|
$58.04
|
+13.79% (+596,625)
|
|||
|
2023 Q2
|
1.18%
|
$63.95
|
-4.08% (-184,216)
|
|||
|
2023 Q1
|
1.35%
|
$69.31
|
+16.87% (+651,213)
|
|||
|
2022 Q4
|
1.23%
|
$71.95
|
-3.30% (-131,559)
|
|||
|
2022 Q3
|
1.41%
|
$71.09
|
-4.29% (-179,101)
|
|||
|
2022 Q2
|
1.44%
|
$77.00
|
+15.04% (+545,445)
|
|||
|
2022 Q1
|
1.00%
|
$73.03
|
+213.73% (+2,470,079)
|
|||
|
2021 Q4
|
0.27%
|
$62.35
|
-1.89% (-22,235)
|
|||
|
2021 Q3
|
0.28%
|
$59.17
|
-19.31% (-281,980)
|
|||
|
2021 Q2
|
0.38%
|
$66.82
|
-0.09% (-1,369)
|
|||
|
2021 Q1
|
0.37%
|
$63.13
|
+0.33% (+4,862)
|
|||
|
2020 Q4
|
0.43%
|
$62.03
|
+0.03% (+366)
|
|||
|
2020 Q3
|
0.55%
|
$60.29
|
-0.45% (-6,644)
|
|||
|
2020 Q2
|
0.56%
|
$58.80
|
-20.35% (-373,749)
|
|||
|
2020 Q1
|
0.77%
|
$55.74
|
-27.64% (-701,418)
|
|||
|
2019 Q4
|
0.76%
|
$64.19
|
-1.55% (-39,851)
|
|||
|
2019 Q3
|
0.71%
|
$50.71
|
new
|
|||
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.